The stock price of Bluebird Bio is likely to face downward pressure in the short term due to the proposed public offering, which typically leads to dilution of existing shares. The lack of pricing details adds uncertainty, contributing to the negative sentiment. The funds' intended use for commercialization and manufacturing of approved gene therapies may be positive in the long term, but the immediate impact of the offering announcement is negative.